Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
hVIVO plc (OPORF)
London, GB
hVIVO plc functions as a contract research organization and pharmaceutical service provider, primarily dedicated to evaluating vaccines and antiviral medications. This is achieved through specialized human challenge clinical trials. The company extends its services to a varied clientele, encompassing major pharmaceutical and biotechnology firms, governmental bodies, and public health agencies. A significant aspect of its operations is a comprehensive array of human challenge study models. These cover conditions such as respiratory syncytial virus (RSV), influenza, human rhinovirus, asthma, malaria, chronic cough, and chronic obstructive pulmonary disease (COPD), with a COVID-19 model currently being developed. Additionally, hVIVO is constructing the 'Disease in Motion' platform, an extensive database focused on infectious disease progression. This platform uniquely integrates diverse datasets, including clinical, immunological, virological, and digital (wearable) biomarkers. The 'Disease in Motion' platform holds broad potential applications for various end-users, from large technology and wearables companies to pharmaceutical and biotech sectors. Further capabilities include offering pre-clinical and early clinical research services, sales and marketing support, and expertise in biometry, data management, and statistics to its European pharmaceutical clients. The company also delivers drug development consultancy, covering Chemistry, Manufacturing, and Controls (CMC), pharmacokinetics (PK), and medical writing for a range of European clients. Formerly known as Open Orphan Plc, the company changed its name to hVIVO plc in October 2022 and is headquartered in London, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -64.13% | -64.13% | -64.13% | -13.90% | -81.28% | +4,363.45% | +4,363.45% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%-25.4% Q4'25: -24.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-156.1% Q4'25: -148.9% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-37.6% Q4'25: -32.7% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-0.8% Q4'25: -26.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-0.9% ★ Q4'25: -61.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-0.4% ★ Q4'25: -1.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.43× ★ Q4'25: -1.14× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 1 EPS Ana. |
Dec 2027 7 Rev. Ana. 1 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.47M
est: 12.17M (-30.4%)
|
15.27M
est: 19.81M (-22.9%)
|
15.45M
est: 21.19M (-27.1%)
|
12.55M
est: 15.13M (-17.1%)
|
3.28M
est: 26.15M (-87.4%)
|
20.60M
est: 34.70M (-40.6%)
|
36.86M
est: 51.46M (-28.4%)
|
50.70M
est: 60.35M (-16.0%)
|
56.04M
est: 71.29M (-21.4%)
|
62.73M
est: 62.68M (+0.1%)
|
46.77M
est: 46.85M (-0.2%)
|
50.53M
48.87M – 51.18M
+7.9% YoY
|
55.05M
51.27M – 56.59M
+8.9% YoY
|
60.19M
57.09M – 61.43M
+9.3% YoY
|
68.14M
64.63M – 69.55M
+13.2% YoY
|
| EBITDA |
520.3K
est: 833.4K (-37.6%)
|
-77.6K
est: 1.36M (-105.7%)
|
-806.1K
est: 1.45M (-155.5%)
|
-3.67M
est: 1.04M (-453.9%)
|
-4.83M
est: 1.79M (-369.6%)
|
-8.55M
est: 2.38M (-459.9%)
|
3.07M
est: 3.53M (-12.9%)
|
7.12M
est: 4.13M (+72.3%)
|
14.02M
est: 4.88M (+187.1%)
|
17.80M
est: 10.65M (+67.1%)
|
4.31M
est: 7.96M (-45.9%)
|
8.59M
8.31M – 8.70M
+7.9% YoY
|
9.36M
8.71M – 9.62M
+8.9% YoY
|
10.23M
9.70M – 10.44M
+9.3% YoY
|
11.58M
10.98M – 11.82M
+13.2% YoY
|
| EBIT |
177.9K
est: 118.7K (+49.9%)
|
-778.2K
est: 193.2K (-502.8%)
|
-1.60M
est: 206.7K (-872.6%)
|
-4.51M
est: 147.6K (-3,156.3%)
|
-5.46M
est: 255.0K (-2,239.3%)
|
-10.61M
est: 338.5K (-3,233.3%)
|
504.0K
est: 502.0K (+0.4%)
|
6.14M
est: 588.7K (+943.4%)
|
11.30M
est: 695.4K (+1,525.3%)
|
14.24M
est: 6.97M (+104.3%)
|
-348.9K
est: 5.21M (-106.7%)
|
5.62M
5.44M – 5.69M
+7.9% YoY
|
6.12M
5.70M – 6.29M
+8.9% YoY
|
6.69M
6.35M – 6.83M
+9.3% YoY
|
7.58M
7.19M – 7.74M
+13.2% YoY
|
| Net Income |
11.1K
est: 3.17M (-99.7%)
|
453.5K
est: 14.36M (-96.8%)
|
-1.37M
est: -20.24M (+93.3%)
|
-4.30M
est: -764.6K (-463.0%)
|
-5.65M
est: -10.28M (+45.0%)
|
-10.79M
est: -6.57M (-64.1%)
|
-74.0K
est: -184.8K (+60.0%)
|
-776.0K
est: 5.14M (-115.1%)
|
16.12M
est: 9.65M (+67.0%)
|
10.65M
est: 11.11M (-4.1%)
|
-5.99M
est: -2.99M (-100.2%)
|
-3.49M
-3.58M – -3.26M
-16.6% YoY
|
-1.10M
-1.13M – -1.03M
+68.4% YoY
|
2.03M
1.89M – 2.08M
+283.6% YoY
|
10.03M
9.36M – 10.30M
+395.3% YoY
|
| SGA |
8.81M
est: 5.67M (+55.4%)
|
16.03M
est: 9.23M (+73.7%)
|
15.77M
est: 9.87M (+59.8%)
|
3.81M
est: 7.05M (-46.0%)
|
1.96M
est: 12.18M (-83.9%)
|
10.96M
est: 16.16M (-32.2%)
|
17.86M
est: 23.97M (-25.5%)
|
23.54M
est: 28.11M (-16.2%)
|
24.17M
est: 33.20M (-27.2%)
|
26.13M
est: 22.53M (+16.0%)
|
—
est: 16.84M (-100.0%)
|
18.16M
17.56M – 18.39M
+7.9% YoY
|
19.78M
18.42M – 20.34M
+8.9% YoY
|
21.63M
20.51M – 22.08M
+9.3% YoY
|
24.49M
23.22M – 24.99M
+13.2% YoY
|
| EPS |
0.00
est: 0.00 (-93.5%)
|
0.01
est: 0.02 (-61.2%)
|
-0.02
est: -0.03 (+23.2%)
|
-0.06
est: 0.00 (-5,265.0%)
|
-0.03
est: -0.01 (-126.9%)
|
-0.02
est: -0.01 (-88.4%)
|
0.00
est: 0.00 (+62.8%)
|
0.00
est: 0.01 (-116.1%)
|
0.02
est: 0.01 (+69.7%)
|
0.02
est: 0.02 (-3.1%)
|
-0.01
est: 0.00 (-99.3%)
|
-0.01
-0.01 – 0.00
-16.6% YoY
|
0.00
0.00 – 0.00
+68.4% YoY
|
0.00
0.00 – 0.00
+283.6% YoY
|
0.01
0.01 – 0.02
+395.3% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yamin Mohammed Khan | Chief Executive Officer & Director | 936.9K | — |
| Stephen Pinkerton | Chief Financial Officer & Executive Director | 469.1K | male |
| Andrew Catchpole | Chief Scientific Officer | — | male |
| Teja Marathe-Sarvadikar | Head of Quality Assurance | — | female |
| Thomas Forst | Chief Medical Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OPORF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
